Initial CX-801 clinical data in advanced melanoma, both as monotherapy and in combination with KEYTRUDA, are expected by the end of 2026, with observed tolerability at doses surpassing the approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results